SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from PDS Biotechnology Corp (PDSB) (CIK 0001472091) (PDSB) — Feb 6, 2020

PDS Biotechnology Corp (PDSB) (CIK 0001472091)
Date: Feb. 6, 2020 · CIK: 0001472091 · Accession: 0001140361-20-002489

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-235549

Date
February 6, 2020
Author
A.G.P./Alliance Global Partners
Form
CORRESP
Company
PDS Biotechnology Corp (PDSB) (CIK 0001472091)

Letter

A.G.P./Alliance Global Partners

590 Madison Avenue

New York, New York 10022

February 6, 2020

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

RE:

PDS Biotechnology Corporation (the “Company”)

File No. 333-235549

Registration Statement on Form S-1

Ladies and Gentlemen:

Reference is made to that certain letter filed as correspondence by A.G.P./Alliance Global Partners, as representative of the underwriters of the offering (the “Representative”), with the U.S. Securities and Exchange Commission via EDGAR on February 5, 2020, in which the Representative joined the Company’s request for the acceleration of the effective date of the above-referenced Registration Statement for Thursday, February 6, 2020 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. The Company is withdrawing such request for acceleration of the effective date and the Representative joins in the request of the Company and hereby formally withdraws its request for acceleration of the effective date at such time.

Very truly yours,
A.G.P./Alliance Global Partners

Show Raw Text
CORRESP
1
filename1.htm

    A.G.P./Alliance Global Partners

    590 Madison Avenue

    New York, New York 10022

    February 6, 2020

    VIA EDGAR

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

      100 F Street, N.E.

      Washington, D.C. 20549

              RE:

                PDS Biotechnology Corporation (the “Company”)

                  File No. 333-235549

                  Registration Statement on Form S-1

    Ladies and Gentlemen:

    Reference is made to that certain letter filed as correspondence by A.G.P./Alliance Global Partners, as representative of the underwriters of the offering (the “Representative”),
      with the U.S. Securities and Exchange Commission via EDGAR on February 5, 2020, in which the Representative joined the Company’s request for the acceleration of the effective date of the above-referenced Registration Statement for Thursday, February
      6, 2020 at 5:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended.  The Company is withdrawing such request for acceleration of the effective date and the Representative
      joins in the request of the Company and hereby formally withdraws its request for acceleration of the effective date at such time.

            Very truly yours,

            A.G.P./Alliance Global Partners

            By:

            /s/ Thomas Higgins

            Name: Thomas Higgins

            Title: Managing Director